studied 50 patients with oligometastatic recurrent prostate cancer (49 with PSMA PET, 10 with choline PET) and found that PSMA PET could help select patients with oligometastatic recurrent prostate cancer suitable for SABR at lower PSA levels and subsequently resulted in a significantly longer response duration (34.0 months vs. 14.7 months) and ADT-free survival (32.7 months vs. 14.9 months) compared with choline PET [24]. The gene discussed is FOLH1; the disease is prostate cancer.